Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0P3SJ
|
||||
Former ID |
DIB014362
|
||||
Drug Name |
XP-21279
|
||||
Synonyms |
Levodopa transported prodrug (Parkinson's disease), XenoPort; L-dopa transported prodrug (Parkinson's disease), XenoPort
|
||||
Indication | Parkinson's disease [ICD9: 332; ICD10:G20] | Phase 2 | [1] | ||
Company |
Xenoport
|
||||
Structure |
![]() |
Download2D MOL |
|||
Canonical SMILES |
c1c(c(cc(c1)C[C@H](N)C(=O)OC[C@H](OC(=O)c1ccccc1)C)O)O.<br />CS(=O)(=O)O
|
||||
Target and Pathway | |||||
Target(s) | D(2) dopamine receptor | Target Info | Agonist | [2] | |
KEGG Pathway | Rap1 signaling pathway | ||||
cAMP signaling pathway | |||||
Neuroactive ligand-receptor interaction | |||||
Gap junction | |||||
Dopaminergic synapse | |||||
Parkinson's disease | |||||
Cocaine addiction | |||||
Alcoholism | |||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
Dopamine receptor mediated signaling pathway | |||||
Nicotine pharmacodynamics pathway | |||||
Reactome | Dopamine receptors | ||||
G alpha (i) signalling events | |||||
WikiPathways | Hypothetical Network for Drug Addiction | ||||
Monoamine GPCRs | |||||
GPCRs, Class A Rhodopsin-like | |||||
Genes and (Common) Pathways Underlying Drug Addiction | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
Nicotine Activity on Dopaminergic Neurons | |||||
References | |||||
REF 1 | ClinicalTrials.gov (NCT01171313) A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet in Parkinson's Disease Subjects. U.S. National Institutes of Health. | ||||
REF 2 | Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. Mov Disord. 2014 Jan;29(1):75-82. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.